<div><strong>By CH Unnikrishnan</strong></div><div> </div><div>India's largest drugmaker by revenue Sun Pharmaceutical Industries Ltd posted almost 50 per cent drop in net profit at Rs 1,106 crore for the quarter ended September 30, as compared to the year ago quarter’s Rs 2,050 crore.</div><div> </div><div>The decline in profit is mainly on the back of a lower sales in all its key markets, including the US and India. Its sales was down 15 per cent at Rs 6,803 crore.</div><div> </div><div>"Our performance for the quarter and first half FY16 has been impacted by lower sales growth, volatile currency movements and supply constraints," said managing director Dilip Shanghvi.</div><div> </div><div>"Nonetheless, we continue to invest significantly in enhancing our specialty and complex generics pipeline. Integration of Ranbaxy is progressing well and while some of the costs have been incurred, the benefits will be visible going forward. We also continue to evaluate opportunities to expand our global foot print," he added.</div>
